A team at Michigan’s Rogel Cancer Center has discovered why some advanced prostate cancers resist standard treatments like enzalutamide. Their research also suggests these patients might respond better to earlier chemotherapy with docetaxel. Read the full article to see how this study could pave the way for more personalized and effective prostate cancer therapies.
We use cookies to ensure you get the best experience on our website. By using this site, you accept our use of cookies.